JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Celldex Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

32.16 -2.25

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

32.08

Max

32.43

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-14M

-81M

Pardavimai

75K

75K

Pelnas, tenkantis vienai akcijai

-1.22

Pelno marža

-108,422.667

Darbuotojai

198

EBITDA

-7.8M

-81M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+75.18% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1B

2.6B

Ankstesnė atidarymo kaina

34.41

Ankstesnė uždarymo kaina

32.16

Naujienos nuotaikos

By Acuity

50%

50%

155 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-03 23:47; UTC

Uždarbis

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

2026-05-03 22:35; UTC

Uždarbis

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

2026-05-03 23:39; UTC

Rinkos pokalbiai

Gold Edge Higher Amid Signs of Resilience -- Market Talk

2026-05-03 23:34; UTC

Rinkos pokalbiai

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

2026-05-03 23:32; UTC

Uždarbis

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

2026-05-03 23:30; UTC

Rinkos pokalbiai

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

2026-05-03 23:20; UTC

Rinkos pokalbiai

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

2026-05-03 23:16; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

2026-05-03 22:57; UTC

Įsigijimai, susijungimai, perėmimai

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

2026-05-03 22:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-03 22:45; UTC

Rinkos pokalbiai

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

2026-05-03 22:20; UTC

Uždarbis

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

2026-05-03 22:08; UTC

Uždarbis

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

2026-05-03 22:05; UTC

Uždarbis

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

2026-05-03 22:05; UTC

Uždarbis

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

2026-05-03 22:05; UTC

Uždarbis

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

2026-05-03 22:04; UTC

Uždarbis

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

2026-05-03 22:03; UTC

Uždarbis

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

2026-05-03 22:03; UTC

Uždarbis

NAB 1H Cash Return on Equity 8.5%>NAB.AU

2026-05-03 22:02; UTC

Uždarbis

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

2026-05-03 22:02; UTC

Uždarbis

NAB 1H Cash Earnings A$2.64B>NAB.AU

2026-05-03 22:02; UTC

Uždarbis

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

2026-05-03 22:01; UTC

Uždarbis

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

2026-05-03 22:01; UTC

Uždarbis

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

2026-05-03 22:01; UTC

Uždarbis

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

2026-05-03 15:06; UTC

Uždarbis

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

75.18% į viršų

12 mėnesių prognozė

Vidutinis 56.6 USD  75.18%

Aukščiausias 90 USD

Žemiausias 34 USD

Remiantis 11 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

11 ratings

10

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

155 / 347 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat